STATEMENT OF
ACTING CHAIRMAN MICHAEL J. COPPS
RE: Investigation of the Spectrum Requirements for Advanced Medical Technologies, ET 
Docket No. 06-135; Amendment of Parts 2 and 95 of the Commission’s Rules to 
Establish the Medical Device Radiocommunication Service at 401-402 and 405-406 
MHz, RM-11271; DexCom, Inc., Request for Waiver of the Frequency Monitoring 
Requirements of the Medical Implant Communications Service Rules, ET Docket  No. 
05-213; Biotronik, Inc., Request for Waiver of the Frequency Monitoring 
Requirements of the Medical Implant Communications Service Rules, ET Docket No. 
03-92
Few uses of our spectrum could be more important than supporting new medical 
technologies that can extend and improve lives. Our nation’s medical researchers continue to 
develop extraordinary body-worn and implanted devices that are used to treat a variety of health 
conditions with less invasive patient treatment options.  Today’s order takes us another major step 
forward with the establishment of a new Medical Device Radiocommunication Service, which 
incorporates the existing Medical Implant Communications Service band with additional 
spectrum for advanced wireless medical radiocommunication devices used for diagnostic and 
therapeutic purposes.  Among other things, these devices are used to control heart rhythms to 
prevent attacks, mitigate the tremors of neurological patients, and control the delivery of insulin 
to patients with diabetes.
I am always pleased to support these kinds of achievements.  Once again I thank our 
Office of Engineering and Technology, working in conjunction with the National 
Telecommunications and Information Administration (NTIA), for developing these new rules.